Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (August 2023)
15 slides from Aim Immunotech's investor presentation, Aug 15, 2023
Slide 1: AIM ImmunoTech
NYSE American: AIM aimimmuno.com AIM ImmunoTech
Slide 2: Forward Looking Statements
Forward Looking Statements ‘Some of the statements included in is presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the “protection of safe harbor for forward-looking statements contained in the Private
Slide 3: Thomas K Equels, M.S., J.D., Chief Executive Officer & President
Slide 4: Focused on Clinical Execution
Focused on Clinical Execution Advancing Toward Additional Clinical and Regulatory Value-Driving Milestones for the Remainder of 2023
Slide 5: Broad Pipeline Across Multiple Unmet Needs
Broad Pipeline Across Multiple Unmet Needs Priority Development Programs Indicati Locally Advanced Approach Ampligen’ Following Phase 3 hlights Patient Recruitment Underway; Pancreatic Adenocarcinoma —_FOLFIRINOX 1* Patient Enrolled Expected Q3 2023 Metastatic Pancreatic Ductal Ampligen and 4 Adenoc
Slide 6: Christopher McAleer, Ph.D., Scientific Officer
Slide 7: Early Access Program in Late-Stage Pancreatic Cancer
Early Access Program in Late-Stage Pancreatic Cancer Indicating Significant Improvement in Progression-Free Survival Study Highlights Status Early Access Program Ongoing Number of Subjects co Study Drug ‘Ampligen” Monotherapy Study Partner Data Publication Positive Results (mabe) Published March 202
Slide 8: Early Access Program in Late-Stage Pancreatic Cancer
Early Access Program in Late-Stage Pancreatic Cancer Overall Survival Overall Survival (57) + Al (W857) + All (127) + Historical Control (0-27) + Historical Control (127) Original Subset (w-27) + Original Subset (W=49) CA19,9 <1000 8 3 8 i Probability of Survival Cy Probability of Survival a 3 r 0 2
Slide 9: Phase 2 Locally Advanced Pancreatic Cancer Enrollment Update
Phase 2 Locally Advance Pancreatic Cancer Enrollment Update Phase 2 Locally Advanced Pancreatic Adenocarcinoma Status Enrollment ongoing. ra Up to.90 Study Drug Ampligen® Following FOLFIRINOX ae SRY _osomoon a Completion of at least four (4) months _ | of first line FOLFIRINOX treatment Identificati
Slide 10: Clinical Update: Additional Priority Oncology Programs
Clinical Update Additional Priority Oncology Programs Investigator Initiated Program Metastatic Pancreatic Ductal Adenocarcinoma Protocol-Planned Interim for Study to Begin oe Results Q3 2023 Ampligen® + Imfinzi Ampligen (durvalumab) Study Drug and KEYTRUDA Study Drug Primary Safety and Efficacy Pri
Slide 11: Ampligen as a Potential Treatment of Post-COVID Chronic Fatigue-Like Conditions
Ampligen® as a Potential Treatment of Post-COVID Chronic Fatigue-Like Conditions ‘Long Haulers’ Share Post-COVID Condition of Fati | igue Extremely Similar Phase 2 Study Characteristics to ME/CFS Completed Enrollment; Status Topline Data expected as Early as Q1 2024 ( . 80 Number of Subjects Fatigue
Slide 12: Thomas K Equels, M.S., J.D., Chief Executive Officer & President
Slide 13: Expecting Multiple Value Driving Milestones
Expecting Multiple Value Driving Milestones Focused on Delivering Results Study Collaborators Astrazeneca? €& MERCK Erasmus MC 13 icy a : Qa NNN Gf $5) University of peourauea 7 i) Brsburgh NOY BUFFETT cancer center
Slide 14: Financial Snapshot
Financial Snapshot Cash Position Expected to Fund Operations Through Multiple Key Milestones Through End of 2024 * Cash, Cash Equivalents and Marketable Securities of $28.4 million as of June 30, 2023 * Research and Development Expenses for the three months ended June 30, 2023, were $3.0 million, co
Slide 15: Why AIM? Why Now?
Achieving clinical and Elevating the AIM regulatory milestones >) story more broadly Why AIM? Why Now? ion of clinical ortunities ore InstItU 15 am